Trial Profile
Phase I Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ Acute Myeloid Leukemia, Myelofibrosis and Chronic Myelomonocytic Leukemia
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 12 Mar 2023
Price :
$35
*
At a glance
- Drugs Tagraxofusp (Primary)
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelofibrosis
- Focus Adverse reactions
- Acronyms HSCT 002
- 17 Jul 2022 Status changed from not yet recruiting to recruiting.
- 01 May 2022 Planned End Date changed from 1 Jul 2026 to 1 Oct 2026.
- 01 May 2022 Planned primary completion date changed from 1 Apr 2024 to 1 Jul 2024.